For example, in breast cancer, different subsets of ECM-myCAFs and Transforming Growth Factor Beta (TGFβ)-myCAFs have been identified; both help tumors evade the immune system and resist immunotherapy by decreasing CD8-positive T cells (CD8+ T) cell infiltration and increasing TGF-β signaling [30,31]. This evidence concerns the gene TGFB1 and breast carcinoma.